Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Authors: Alegre Amor, Adrian, Baldini, Luca, Beksac, Meral, Belotti, Angelo, Benboubker, Lotfi, Besemer, Britta, Besisik, Sevgi, Bila, Jelena, Boccadoro, Mario, Cavo, Michele, De La Rubia Comos, Javier, Delimpasi, Sosana, Dimopoulos, Meletios A., Doyen, Chantal, Dytfeld, Dominik, Engelhardt, Monika, Facon, Thierry, Foà, Roberto, Goldschmidt, Hartmut, Grosicki, Sebastian, Hajek, Roman, Hayri Ozsan, Guner, Hulin, Cyrille, Iversen, Brian, Karlin, Lionel, Katodritou, Eirini, Knop, Stefan, Kyrtsonis, Marie-Christine, Lahuerta, Juan Jose, Leleu, Xavier, Martinez Chamorro, Carmen, Mateos Manteca, María-Victoria, Meuleman, Nathalie, Minnema, Monique, Moreau, Philippe, Offidani, Massino, Oriol Rocafiguera, Albert, Pehlivan, Mustafa, Pour, Ludek, Roerdink, Henk Th.J., Rosinol Dacsh, Laura, Salwender, Hans, Sonneveld, Pieter, Symeonidis, Anargyros, Toftmann Hansen, Charlotte, Tuglular, Tulin, Unal, Ali, Vlummens, Philip, Vural, Filiz, Wu, Ka Lung, Zweegman, Sonja, Dimopoulos, Meletios A ^*, Terpos, Evangelos, Symeonidis, Argiris, Oriol, Albert, Mateos, Maria-Victoria, Einsele, Hermann, Orfanidis, Ioannis, Ahmadi, Tahamtan, Ukropec, Jon, Kampfenkel, Tobias, Schecter, Jordan M, Qiu, Yanping, Amin, Himal, Vermeulen, Jessica, Carson, Robin

Source: In The Lancet Oncology June 2021 22(6):801-812